secretagogue is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-11-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Researchers at a pharmaceutical company first described it in the 1990s while screening small peptides for growth hormone releasing activity. Its chain contains five amino acid residues, two of which are non-natural building blocks, including 2-aminoisobutyric acid and a naphthylalanine derivative. The molecule was designed to act at the ghrelin receptor while avoiding several effects observed with earlier secretagogues.
At the cellular level, ipamorelin binds the growth hormone secretagogue receptor, also called the ghrelin receptor. Activation of this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to release of growth hormone into circulation. Because release follows a pulsatile pattern, studies often report peak concentration and total area under the curve rather than a single time point. Selectivity for this receptor is the property most frequently discussed in comparative work.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentapeptide | Growth hormone secretagogue family |
| Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 | Contains two non-natural residues |
| Molecular formula | C38H49N9O5 | Free base form |
| Molecular weight | 711.85 g/mol | Calculated from formula |
| Primary target | GHS-R1a ghrelin receptor | Agonist activity |
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
Ipamorelin 是一种合成五肽，在 20 世纪 90 年代被报道为生长激素促分泌剂。其结构基于胃饥饿素受体激动剂的设计思路，但并非天然激素。早期药理学研究显示，它可刺激垂体释放生长激素，而对应激激素轴的影响相对较小。该化合物常被用作研究生长激素调节通路的工具分子。
在机制层面，ipamorelin 与生长激素促分泌受体 1a 型结合，该受体也介导胃饥饿素的多种效应。受体激活后，细胞内信号促进生长激素从垂体前叶释放。由于对促肾上腺皮质激素和皮质醇的刺激较弱，它被视为选择性较高的促分泌剂。这种选择性在动物模型和少量人体研究中被观察到，但人体数据仍然有限。
现有文献多来自小规模、短期的研究，涉及生长激素缺乏、术后肠麻痹等方向。长期使用是否导致受体脱敏，以及重复给药后效应是否衰减，仍属开放问题。不同研究之间的剂量、给药途径和受试者特征差异较大，因此结论外推需谨慎。关于临床获益的确切证据尚不充分，需要更大规模的对照试验来澄清。
Piggott; Fermented Beverage Production, Kluwer Academic/Plenum Publishers, 2003, ISBN 0-306-47706-8 McFarland, Ben; World's Best Beers, Sterling Publishing, 2009, ISBN 978-1-4027-6694-7 Oliver, Garrett (ed); The Oxford Companion to Beer, Oxford University Press, 2011 Priest, Fergus G.; Handbook of Brewing, CRC Press, 2006, ISBN 0-8247-2657-X Rabin, Dan and Forget, Carl; The Dictionary of Beer and Brewing, Fitzroy Dearborn/Taylor & Francis, 1998 ISBN 978-1-57958-078-0 Stevens, Roger, et al.; Brewing: Science and Practice, Woodhead Publishing, 2004, ISBN 0-8493-2547-1 Unger, Richard W.; Beer in the Middle Ages and the Renaissance, University of Pennsylvania Press, 2004, ISBN 0-8122-3795-1
=== Films === In the 1999 film Austin Powers: The Spy Who Shagged Me, it is stated by Number 2 (Robert Wagner) to Dr. Evil (Mike Myers), that while he was frozen, Virtucon invested in the company years prior which has become a major conglomerate. In the 2021 film Ghostbusters: Afterlife, it is stated by Ray Stantz (Dan Aykroyd) that Starbucks had taken over the Ghostbusters' firehouse headquarters at North Moore Street after they went out of business and had turned it into a coffeehouse before Winston Zeddemore (Ernie Hudson) bought it back from them.
== Death == Farthing died on 6 April 2014 of a heart attack while travelling in a taxi in Hong Kong. His funeral was held at Church of St Michael and All Angels, an Anglican church in Christchurch on 22 April 2014. He is buried on Banks Peninsula.
5-HT2C receptor agonists are a class of drugs that activate 5-HT2C receptors. They have been investigated for the treatment of a number of conditions including obesity, psychiatric disorders, sexual dysfunction and urinary incontinence. The 5-HT2C receptors are one of three subtypes that belong to the serotonin 5-HT2 receptor subfamily along with 5-HT2A and 5-HT2B receptors. The development of 5-HT2C agonists has been a major obstacle, because of severe side effects due to a lack of selectivity. Activation of 5-HT2A receptors can induce hallucinations, and the activation of 5-HT2B receptors has been implicated in cardiac valvular insufficiency and possibly in pulmonary hypertension.
Sources: en.wikipedia.org
=== Recent studies === A 2019 study looked at freeze-dried extracts of the Rotheca myricoides and found that they possess significant anti-hyperglycemic and antidyslipidemic effects on a type 2 diabetes rat model. The antidyslipidemic effects included decreased total plasma cholesterol, LDL-cholesterol, serum triglyceride and increased HDL-cholesterol. The freeze-dried extracts also lowered the serum uric levels and hepatic triglycerides and hepatic weight. This study confirms the effectiveness of the traditional medicine to manage diabetes in Kenya. The mechanism for the antidiabetic effects is due to the modulation of PPAR-γ. A 2008 study found that Rotheca myricoides had antimutagenic properties. The leaf extract of the species and DCM and MeOH extracts shows clear anti-mutagenicity. The antimutagenic properties were seen even at low doses of 0.05 mg/L. Rotheca myricoides is one ingredient (along with four African medicinal plants: Clerodendrum glabrum E. Mey., Lamiaceae, Gladiolus dalenii van Geel, and Senna occidentalis (L.) Link) in a new COVID-19 therapeutic candidate called PHELA. In vitro testing found that PHELA inhibited >90% of SARS-CoV-2 and SARS-CoV infection at concentration levels of 0.005 mg/mL to 0.03 mg/mL. They also found that PHELA had very strong binding energy interactions with SARS-CoV-2 proteins.
Any public or private entity or agency or medical or dental facility where clinical trials are conducted. (ICH E6) Any public or private entity or agency (including Federal, State, and other agencies). (21CFR50.3) Institutional Review Board (IRB)
"The soy foods movement began in small pockets of the counterculture, notably the Tennessee commune named simply The Farm, but by the mid-1970s a vegetarian revival helped it gain momentum and even popular awareness through books such as The Book of Tofu." Although practically unseen in 1900, by 2000 soybean plantings covered more than 70 million acres, second only to corn, and it became America's largest cash crop. In 2021, 87,195,000 acres were planted, with the largest acreage in the states of Illinois, Iowa, and Minnesota.
Sources: en.wikipedia.org
It is a synthetic pentapeptide in the growth hormone secretagogue family. The chain contains five residues, two of which are non-natural amino acids.
It acts as an agonist at the growth hormone secretagogue receptor, also known as the ghrelin receptor. Binding at pituitary somatotroph cells promotes growth hormone release.
Early studies report weaker effects on cortisol, prolactin, and appetite than compounds such as GHRP-6. The size of that difference in humans is not firmly established.
The peptide is Aib-His-D-2-Nal-D-Phe-Lys-NH2. Two of its residues are non-natural, which slows enzymatic degradation. The C-terminal amide is common among bioactive peptides.